Related Experiment Video
Updated: Jun 4, 2025

Application of CRISPR Interference CRISPRi for Gene Silencing in Pathogenic Species of Leptospira
Published on: August 14, 2021
In silico prediction and experimental evaluation of LIP3228 of pathogenic Leptospira as a potential subunit vaccine
Yaowarin Nakornpakdee1, Teerasit Techawiwattanaboon2, Saowaros Prasai1
1Department of Pathobiology, Faculty of Science, Mahidol University, Ratchathewi, Bangkok, 10400, Thailand.
Abstract:
A protein subunit vaccine comprising conserved surface-exposed outer membrane proteins (SE-OMPs) is considered a promising platform for leptospirosis vaccine. The search for novel vaccine candidates that confer high protective efficacy against leptospirosis is ongoing. The LIP3228 protein was previously identified as a conserved and abundant SE-OMP with the potential to serve as an effective vaccine candidate. However, it is crucial to explore the immunological properties of this vaccine antigen before proceeding with animal experiments. This study aimed to assess the immunological characteristics of LIP3228 through in silico prediction and to validate its immunogenicity and protective efficacy in a hamster model of acute leptospirosis. The LIP3228 vaccine candidate was predicted in silico to be immunogenic, with strong binding B-cell and T-cell epitopes. In the immune simulator, it demonstrated stable interactions with Toll-like receptors 2 (TLR2) and 4 (TLR4) and induced immune responses, potentially stimulating host immune responses in vivo. The animal experiment showed that immunization with recombinant LIP3228 protein, formulated with AddaVax adjuvant, induced high and specific IgG responses in hamsters, with IgG2 being the predominant subclass. Although no significant improvement in survival was observed compared to the negative control after a homologous challenge with virulent leptospires, the vaccinated hamsters showed a reduction in histopathological changes and severity of lesions in target organs compared to unvaccinated hamsters. These results suggest that the immunoinformatic prediction is effective in predicting immunogenicity but not protective efficacy. Therefore, LIP3228 could be considered a potential vaccine candidate for mitigating severe tissue damage. These findings may have significant implications for the development of subunit vaccines in the future.
Insights
This study explored the LIP3228 protein as a potential leptospirosis vaccine. While it showed immunogenicity and reduced tissue damage in hamsters, it did not improve survival rates, suggesting potential for mitigating disease severity.
Area of Science:
- Vaccinology
- Immunology
- Infectious Diseases
Background:
- Leptospirosis remains a global health concern, necessitating novel vaccine strategies.
- Protein subunit vaccines utilizing conserved surface-exposed outer membrane proteins (SE-OMPs) are promising for leptospirosis.
- The LIP3228 protein is a conserved SE-OMP identified as a potential vaccine candidate.
Purpose of the Study:
- To assess the in silico immunological properties of the LIP3228 protein.
- To validate the immunogenicity and protective efficacy of LIP3228 in a hamster model of leptospirosis.
Main Methods:
- In silico immunoinformatic predictions of B-cell and T-cell epitopes.
- Immune simulator analysis of interactions with Toll-like receptors (TLR2 and TLR4).
- Hamster immunization with recombinant LIP3228 and AddaVax adjuvant, followed by challenge with virulent Leptospira.
Main Results:
- In silico analysis predicted LIP3228 to be immunogenic with strong epitope binding.
- Immunization induced high, specific IgG responses in hamsters, predominantly IgG2.
- Vaccinated hamsters exhibited reduced histopathological damage and lesion severity, but no significant survival improvement.
Conclusions:
- Immunoinformatic prediction effectively indicated immunogenicity but not protective efficacy.
- LIP3228 shows potential as a vaccine candidate for reducing leptospirosis-associated tissue damage.
- Further research into LIP3228 and similar subunit antigens is warranted for future vaccine development.

